In This Article:
Tilray Brands (NASDAQ:TLRY) Second Quarter 2025 Results
Key Financial Results
-
Revenue: US$211.0m (up 8.9% from 2Q 2024).
-
Net loss: US$85.3m (loss widened by 74% from 2Q 2024).
-
US$0.099 loss per share (further deteriorated from US$0.067 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tilray Brands Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 150%.
Looking ahead, revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 12% from a week ago.
Risk Analysis
Be aware that Tilray Brands is showing 1 warning sign in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.